The data from the TROPION-Lung05 trial, showing very promising antitumor activity in a heavily pretreated EGFR mutant NSCLC population, open the road to further phase III development of datopotamab deruxtecan in this clinical context, with a mechanism of action that goes beyond EGFR pathway. This evidence concerns the gene EGFR and non-small cell lung carcinoma.